CN115190800A - 一种brd4抑制剂的用途 - Google Patents
一种brd4抑制剂的用途 Download PDFInfo
- Publication number
- CN115190800A CN115190800A CN202180017690.XA CN202180017690A CN115190800A CN 115190800 A CN115190800 A CN 115190800A CN 202180017690 A CN202180017690 A CN 202180017690A CN 115190800 A CN115190800 A CN 115190800A
- Authority
- CN
- China
- Prior art keywords
- compound
- tumor
- solid tumor
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种BDR4抑制剂在制备***、尤其是治疗晚期实体瘤或难治性实体瘤的药物中的应用，该药物治疗晚期实体瘤或难治性实体瘤的治疗方案和安全有效剂量。该BDR4抑制剂能有效治疗晚期实体瘤或难治性实体瘤，对晚期或难治性的乳腺癌、结直肠癌、***癌、胃肠肿瘤等有确切疗效，并且临床安全性较好。
Description
PCT国内申请，说明书已公开。
Claims (14)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010156960 | 2020-03-09 | ||
| CN2020101569602 | 2020-03-09 | ||
| PCT/CN2021/079672 WO2021180055A1 (zh) | 2020-03-09 | 2021-03-09 | 一种brd4抑制剂的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115190800A true CN115190800A (zh) | 2022-10-14 |
Family
ID=77671222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180017690.XA Pending CN115190800A (zh) | 2020-03-09 | 2021-03-09 | 一种brd4抑制剂的用途 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115190800A (zh) |
| WO (1) | WO2021180055A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115894678B (zh) * | 2022-07-15 | 2023-10-20 | 新疆赛尔托马斯生物科技有限公司 | 一种干细胞细胞因子的制备方法及其在制备药品中的用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019056950A1 (zh) * | 2017-09-22 | 2019-03-28 | 南京明德新药研发股份有限公司 | 噻吩并二氮杂卓衍生物及其应用 |
| CN113646312A (zh) * | 2019-03-22 | 2021-11-12 | 石药集团中奇制药技术（石家庄）有限公司 | 固体形式的brd4抑制剂化合物及其制备方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015153871A2 (en) * | 2014-04-04 | 2015-10-08 | Constellation Pharmaceuticals, Inc. | EXPRESSION LEVELS OF BCL-xL, BCL2, BCL-w, AND BAD AND CANCER THERAPIES |
| WO2016156905A1 (en) * | 2015-04-03 | 2016-10-06 | Oncoethix Gmbh | Pharmaceutical doses for a bromodomain and extraterminal protein (bet) inhibitor |
| WO2016196065A1 (en) * | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Methods and compositions for assessing responsiveness of cancers to bet inhibitors |
-
2021
- 2021-03-09 CN CN202180017690.XA patent/CN115190800A/zh active Pending
- 2021-03-09 WO PCT/CN2021/079672 patent/WO2021180055A1/zh active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019056950A1 (zh) * | 2017-09-22 | 2019-03-28 | 南京明德新药研发股份有限公司 | 噻吩并二氮杂卓衍生物及其应用 |
| CN113646312A (zh) * | 2019-03-22 | 2021-11-12 | 石药集团中奇制药技术（石家庄）有限公司 | 固体形式的brd4抑制剂化合物及其制备方法与应用 |
Non-Patent Citations (1)
| Title |
|---|
| 赵刚主编: "《常见肛肠病图谱》", 人民军医出版社, pages: 88 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021180055A1 (zh) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3076972B1 (en) | Cancer treatment with combination of plinabulin and taxane | |
| EP2269604B1 (en) | Treatment of solid kidney tumours with a rapamycin derivative | |
| US20070281040A1 (en) | Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents | |
| JP2012500180A5 (zh) | ||
| US11576919B2 (en) | Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant | |
| JP2015512388A (ja) | 併用療法 | |
| CN115135649A (zh) | 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合 | |
| JP2022501394A (ja) | Ｍｄｍ２阻害剤の医薬組成物、並びに疾患を予防及び／又は治療するためのその使用 | |
| US20150072020A1 (en) | Dexanabinol or a Derivative Thereof for Use in the Treatment of Cancer in Dose Ranges of 2-30 mg/kg | |
| CN115190800A (zh) | 一种brd4抑制剂的用途 | |
| EP4159238A1 (en) | Combined pharmaceutical composition of c-met kinase inhibitor and anti-pd-l1 antibody | |
| CA2437768A1 (en) | Targetted anti-tumor drug delivery systems | |
| US20230038138A1 (en) | Combination therapy for treating cancer | |
| WO2021185234A1 (zh) | 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途 | |
| TW202029961A (zh) | Ar拮抗劑聯合parp抑制劑在製備治療***癌的藥物中的用途 | |
| KR100844477B1 (ko) | 항종양 효과 증강제, 항종양제 및 암 치료 방법 | |
| TWI843217B (zh) | 一種藥物組合及其應用 | |
| WO2021228146A1 (zh) | 一种lsd1抑制剂的用途 | |
| CN117357528A (zh) | 一种激酶抑制剂的新用途 | |
| US20230404971A1 (en) | Combination Comprising Abemaciclib and 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid | |
| US20240197739A1 (en) | Combination Comprising Ribociclib and Amcenestrant | |
| CN117919234A (zh) | 一种萘酰胺化合物治疗耐药性肿瘤的用途 | |
| TW202308641A (zh) | 用於治療癌症之方法及包含cdk抑制劑之給藥方案 | |
| CN117940164A (zh) | 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途 | |
| AU2021382148A9 (en) | Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |